Q1 2026 Capricor Therapeutics Inc Earnings Call Transcript
Key Points
- Capricor Therapeutics Inc (CAPR) has a strong balance sheet with approximately $279 million in cash equivalents and marketable securities, providing sufficient capital to fund operations into the fourth quarter of 2027.
- The HOPE-3 Phase III trial results for Daramicel demonstrated significant efficacy, with a 54% reduction in disease severity at 12 months and a 91% slowing of disease progression in cardiomyopathy patients.
- The FDA has accepted the Biologics License Application (BLA) for Daramicel as complete, and the review is actively progressing with a PDUFA target action date of August 22, 2026.
- Capricor Therapeutics Inc (CAPR) has completed over 800 intravenous infusions of Daramicel, showing a consistent and well-tolerated safety profile.
- The company is expanding its manufacturing capacity, with plans to support treatment for approximately 2,000 to 2,500 patients per year by 2027, ensuring readiness for commercial launch.
- Capricor Therapeutics Inc (CAPR) is involved in a legal dispute with NS Pharma and Nippon Shinyaku over a flawed pricing structure in their distribution agreement, which could delay the commercialization of Daramicel.
- The company has not recognized any revenue for the first quarter of 2026, reflecting ongoing financial challenges.
- Operating expenses increased significantly to $36.8 million in Q1 2026 from $25 million in Q1 2025, driven by investments in clinical, regulatory, and manufacturing activities.
- The lawsuit with NS Pharma may impact Capricor Therapeutics Inc (CAPR)'s ability to distribute Daramicel efficiently, depending on the court's decision.
- Capricor Therapeutics Inc (CAPR) is still in the process of building a commercial team and infrastructure, which may affect the timing and effectiveness of the product launch.
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics first quarter 2026 conference call. At this time, all participant lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press *0 for the operator. This call is being recorded on Tuesday, May 12th, 2022.
I would now like to turn the conference over to our CFO, AJ Bergman, for the forward-looking statement. Please go ahead.
Thank you, and good afternoon, everyone.
Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, potential regulatory developments involving our product candidates, our future R&D plans, our anticipated conduct and timing of preclinical and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
